AI-powered platform to develop personalized medicines for chronic skin diseases
CompanyIntegraSkin GmbH, Ihlow, Germany
The company IntegraSkin specializes in the development of personalized medications for chronic skin diseases (CISCs). To screen for effective drug candidates, the company has developed an AI-supported platform that compares multimodal patient data with a large-scale OMICs database for its analyses. To develop a personalized treatment strategy, the AI examines, among other things, tissue samples from diseased areas of the patient's skin and compares them with skin samples from unaffected areas. The patient's individual lifestyle and diet are also taken into account. Specially developed algorithms enable accelerated and safe screening for disease-associated patterns and biomarkers, potential drug candidates and their possible targets. In summary, the platform offers doctors and researchers a comprehensive diagnostic and analysis tool for more in-depth, general or individual research into CISCs. The method offers high potential for generating new insights and can thereby help accelerate drug development and optimize existing non-specific therapeutic approaches. The company makes its databases available to researchers and also offers services for those affected.
One step ahead in AI for personalized medicine.
www.integraskin.de
Added on: 04-30-2024
[1] https://integraskin.de/[2] https://integraskin.de/our-services/
